ar-42
Small moleculeexperimental
Clinical trial activity
5 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 4, 2010 (NCT01129193)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Burkitt Lymphoma · Phase 1
- Carcinoma, Renal Cell · Phase 1
- Hodgkin Disease · Phase 1
- Intraocular Lymphoma · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Leukemia-Lymphoma, Adult T-Cell · Phase 1
- Leukemia, Myeloid, Acute · Phase 1
- Leukemia, Prolymphocytic · Phase 1
- Lymphoma · Phase 1
- Lymphoma, B-Cell, Marginal Zone · Phase 1
- Lymphoma, Follicular · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 1
- Lymphoma, Large-Cell, Anaplastic · Phase 1
- Lymphoma, Large-Cell, Immunoblastic · Phase 1
- Lymphoma, Mantle-Cell · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Lymphoma, Primary Cutaneous Anaplastic Large Cell · Phase 1
- Lymphoma, T-Cell · Phase 1
- Lymphoma, T-Cell, Peripheral · Phase 1
- Lymphomatoid Granulomatosis · Phase 1
- Meningioma · Early Phase 1
- Multiple Myeloma · Phase 1
- Neoplasm Metastasis · Phase 1
- Neurofibromatosis 2 · Early Phase 1
- Neuroma, Acoustic · Early Phase 1
- Sarcoma · Phase 1
- Sezary Syndrome · Phase 1
- Testicular Neoplasms · Phase 1
- Transplantation · Phase 1
- Waldenstrom Macroglobulinemia · Phase 1
Mechanism of action
- Histone deacetylase 2INHIBITOR
HDAC2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)[C@H](C(=O)Nc1ccc(C(=O)NO)cc1)c1ccccc1- Mol. weight
- 312.37 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL191482 ↗
Also known as
- ar-42
- ar-42
- ar-42
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02795819 | Phase 1 | Jul 8, 2016 | Arno Therapeutics, National Cancer Institute (NCI), Virginia Commonwealth University |
| NCT02569320 | Phase 1 | May 9, 2016 | Celgene, Ohio State University |
| NCT02282917 | Early Phase 1 (Phase 1) | Sep 1, 2015 | Harvard University, Johns Hopkins University, Mayo Clinic, Ohio State University, Stanford University |
| NCT01798901 | Phase 1 | Sep 17, 2013 | Ohio State University |
| NCT01129193 | Phase 1 | May 4, 2010 | Arno Therapeutics, National Cancer Institute (NCI), Ohio State University |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ohio State University | Academic/Hospital | 4 | 3 | 1 | 2010 |
| Arno Therapeutics | For profit | 2 | 0 | 1 | 2010 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 1 | 2010 |
| Celgene | For profit | 1 | 0 | 1 | 2016 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Stanford University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Virginia Commonwealth University | Academic/Hospital | 1 | 1 | 1 | 2016 |
9 organizations
Page 1 / 1